Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Mometasone furoate in the management of asthma: a review

Authors Tan RA, Corren J

Published 5 December 2008 Volume 2008:4(6) Pages 1201—1208


Review by Single-blind

Peer reviewer comments 2

Ricardo A Tan1, Jonathan Corren2

1California Allergy and Asthma Medical Group, Los Angeles, CA; 2Allergy Research Foundation, Los Angeles, CA, USA

Abstract: Inhaled corticosteroids (ICS) have proven to be the most effective and essential therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to severe persistent asthma. Mometasone furoate (MF) is a relatively new ICS agent with high affinity for the glucocorticoid receptor. It is approved in the US for maintenance treatment of asthma for patients 4 years of age and older. It has been shown to be well tolerated with no significant adverse side effects observed in clinical trials and post-marketing surveillance. The efficacy of mometasone furoate has been established in large, well-designed studies. In patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ICS, once-daily MF has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone. Twice-daily dosing with MF has been demonstrated to successfully allow for reduction or elimination of oral corticosteroids in severe asthmatics.

Keywords: inhaled steroids, mometasone furoate, once-daily dosing, asthma, stepwise approach

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Immunosuppressive effects of the standardized extract of Phyllanthus amarus on cellular immune responses in Wistar-Kyoto rats

Ilangkovan M, Jantan I, Mesaik MA, Bukhari SNA

Drug Design, Development and Therapy 2015, 9:4917-4930

Published Date: 26 August 2015

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:1217-1224

Published Date: 24 February 2015

Microemulsion-based synergistic dual-drug codelivery system for enhanced apoptosis of tumor cells

Qu D, Ma Y, Sun W, Chen Y, Zhou J, Liu C, Huang M

International Journal of Nanomedicine 2015, 10:1173-1187

Published Date: 5 February 2015

Synthesis and in vitro antineoplastic evaluation of silver nanoparticles mediated by Agrimoniae herba extract

Qu D, Sun W, Chen Y, Zhou J, Liu C

International Journal of Nanomedicine 2014, 9:1871-1882

Published Date: 15 April 2014

Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering

Chen YP, Zheng XW, Chen G, He C, Zhu WF, Feng SY, Xi G, Chen R, Lan FH, Zeng HS

International Journal of Nanomedicine 2012, 7:73-82

Published Date: 30 December 2011

The comparison of protein-entrapped liposomes and lipoparticles: preparation, characterization, and efficacy of cellular uptake

Chang WK, Tai YJ, Chiang CH, Hu CS, Hong PD, Yeh MK

International Journal of Nanomedicine 2011, 6:2403-2417

Published Date: 20 October 2011

Immune response profiles after caterpillar exposure: a case report

Tamar A Smith-Norowitz, Kevin B Norowitz, Stephan Kohlhoff, et al

Journal of Inflammation Research 2010, 3:45-51

Published Date: 16 July 2010

Inhibitory effects of zinc hyaluronate on synoviocyte growth and matrix metalloproteinase-9 activity

Seiji Saito, Keisei Maekawa, Shigeru Kotake

Journal of Inflammation Research 2009, 2:45-57

Published Date: 17 November 2009